(Total Views: 759)
Posted On: 07/21/2020 7:47:46 PM
Post# of 153908
Quote:
The data safety data suggests that the Leronlimab group will have better outcomes than the placebo group as less patients progressed to severe conditions as measured by SAE.
Read More: https://investorshangout.com/post/newpost/605...z6SsNWBCjM
One point I would like to add: SAE can happen at anytime. It's entirely possible, and quite likely, that some of the SAE in the treatment arm occurred early on, before Leronlimab had a chance to work.
Why is this important? Because our primary endpoint is the improvement of symptoms. This creates a situation where it is entirely likely that the p value power of the primary endpoint will be STRONGER than the SAE alone.
(4)
(0)
